First set of comments from the December 2016 special Psilocybin issue of the Journal of Psychopharmacology
For this study, 1993 individuals (mean age 30 yrs; 78% male) completed an online survey about their single most psychologically difficult or challenging experience (worst “bad trip”) after consuming…
A randomized double-blind trial: High-dose psilocybin produced large decreases in clinician- and self-rated measures of depressed mood and anxiety, along with increases…
The Trip Treatment: On an April Monday in 2010, Patrick Mettes, a fifty-four-year-old television news director being treated for a cancer of the bile ducts, read an article on the front page…
A new study by The University of South Florida has found that low doses of the active ingredient in magic mushrooms repairs brain damage caused by extreme trauma, offering renewed hope to millions of…
Editorial by David Nutt from the special Psilocybin issue of the Journal of Psychopharmacology vol 30, 2016.
This special issue of the Journal of Psychopharmacology contains two landmark…
First study from the December 2016 special Psilocybin issue of the Journal of Psychopharmacology, by Ross et al (with great thanks to all the authors)
Psilocybin is known for captivating its imbiber with novel thought and emotional surrender. These mystical experiences can be powerful enough to affect one’s perception and leave an imprint on…